GRPH News and Press, Graphite Bio Inc. From 11/15/23

2023-11-15 07:36:44 ET More on Graphite Bio Seeking Alpha’s Quant Rating on Graphite Bio Historical earnings data for Graphite Bio Financial information for Graphite Bio For further details see: Graphite Bio in reverse merger with LENZ Therapeutics...

- Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Graphite Bio Inc. (GRPH) is expected to report $-0.25 for Q3 2023

2023-10-31 12:46:31 ET More on Eli Lilly Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Eli Lilly: Do Not Chase This Stock Over The Cliff ...

2023-06-23 07:03:40 ET Graphite Bio ( NASDAQ: GRPH ) CFO Alethia Young to step down to pursue other opportunities. Ms. Young will remain through June 30, 2023 to oversee her current responsibilities and ensure an orderly transition. Source: Press Release ...

Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensure an or...

2023-05-26 01:55:00 ET Summary Gene editing concern Graphite Bio has suffered some setbacks since we first looked at the company in the Spring of 2022. However, the stock has moved higher since we last visited with Graphite and the company continues to sit on a large cash hoard. ...

2023-05-24 07:24:00 ET Novo Nordisk ( NVO ) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced Wednesday. Under the partnership, two companies will focus ...

2023-03-20 16:29:39 ET Graphite Bio press release ( NASDAQ: GRPH ): Q4 GAAP EPS of -$0.44 beats by $0.07 . As of December 31, 2022, cash, cash equivalents and investments in marketable securities totaled $283.6 million. For further details see: Graphite Bio G...